SLAMF7 and Miyoshi myopathy: Preclinical studies preliminarily verified the efficacy and safety of SLAMF7-CAR NK cells, natural killer group 2 member D (NKG2D)-CAR NK cells, and BCMA-CAR NK cells in MM [19, 126, 127].